4.7 Article

APOE genotype and early β-amyloid accumulation in older adults without dementia

Journal

NEUROLOGY
Volume 89, Issue 10, Pages 1028-1034

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0000000000004336

Keywords

-

Funding

  1. Alzheimer's Disease Neuroimaging Initiative (ADNI) (NIH) [U01 AG024904]
  2. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  3. National Institute on Aging
  4. National Institute of Biomedical Imaging and Bioengineering
  5. AbbVie
  6. Alzheimer's Association
  7. Alzheimer's Drug Discovery Foundation
  8. Araclon Biotech
  9. Bio-Clinica, Inc.
  10. Biogen
  11. Bristol-Myers Squibb Company
  12. CereSpir, Inc.
  13. Cogstate
  14. Eisai Inc.
  15. Elan Pharmaceuticals, Inc.
  16. Eli Lilly and Company
  17. EuroImmun
  18. F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.
  19. Fujirebio
  20. GE Healthcare
  21. IXICO Ltd.
  22. Janssen Alzheimer Immunotherapy Research & Development, LLC
  23. Johnson & Johnson Pharmaceutical Research & Development LLC
  24. Lumosity
  25. Lundbeck
  26. Merck Co., Inc.
  27. Meso Scale Diagnostics, LLC
  28. NeuroRx Research
  29. Neurotrack Technologies
  30. Novartis Pharmaceuticals Corporation
  31. Pfizer Inc.
  32. Piramal Imaging
  33. Servier
  34. Takeda Pharmaceutical Company
  35. Transition Therapeutics
  36. Canadian Institutes of Health Research
  37. National Health & Medical Research Council-Australian Research Council (NHMRC-ARC) Dementia Research Development Fellowship [APP1111603]
  38. NIH [K01 AG051718]

Ask authors/readers for more resources

Objective: To clarify associations between APOE epsilon 4 allele and age on longitudinal rates of b-amyloid (Ab) accumulation within A beta+ and A beta-older individuals without dementia. Methods: We analyzed 595 older adults without dementia classified cross-sectionally as A beta- (n 5 325) and A beta+ (n 5 270) using longitudinal florbetapir PET. The influence of age and APOE genotype on longitudinal accumulation of Ab was examined with linear mixed models. Results: APOE epsilon 4 and older age were associated with higher risk of being classified as A beta+ at baseline. The annual rate of Ab accumulation was significantly greater than zero for A beta-epsilon 3 (0.0021 6 0.0007 standardized uptake value ratio [ SUVR] units) and A beta-epsilon 4 (0.0044 6 0.0010 SUVR units), as well as A beta+ epsilon 3 (0.0141 6 0.0019 SUVR units) and A beta+ epsilon 4 (0.0126 6 0.0018 SUVR units). Ab accumulation was significantly faster in A beta-epsilon 4 compared to A beta-epsilon 3 and A beta-epsilon 2. Rates of Ab accumulation did not differ significantly between A beta+ APOE groups. Older age was associated with higher rates of Ab accumulation in the A beta-group. Conclusions: APOE epsilon 4 carriage and older age were predictors of longitudinal Ab accumulation within the A beta-group but not the A beta+ group. APOE epsilon 2 carriage was protective against longitudinal Ab accumulation within the A beta-group. APOE genotype in conjunction with chronologic age may aid in participant selection for primary prevention trials aimed at halting Ab accumulation before abnormal levels are reached.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available